


Hypervalent Iodine Mediated Synthesis of C-2 Deoxy Glycosides and Amino Acid Glycoconjugates

Maidul Islam, Nishanth D. Tirukoti, Shyamapada Nandi, and Srinivas Hotha*

Department of Chemistry, Indian Institute of Science Education and Research, Pune 411 008, India

S Supporting Information

ABSTRACT: A simple, efficient, and practical method for the synthesis of C-2 deoxy-2-iodo glycoconjugates in self-assembled structures was found using $\text{PhI}(\text{OCOR})_2$. 2-Iodo glycoserinyl esters were intramolecularly converted into 2-iodo serinyl glycosides which upon dehalogenation gave C-2 deoxy amino acid glycoconjugates.



INTRODUCTION

Stereo- and regioselective reactions are well sought after in organic chemistry; frequently, stereo- and regioselectivities are obtained by taking advantage of steric environments such as chiral auxiliaries, reagents, and solvents.¹ The utility of self-assembled structures for the above is a promising alternative.² It is desirable that the self-assembled structure (i) is stable at the temperature of the reaction; (ii) does not react with reagents; (iii) does not disassemble during the reaction; and (iv) should be accessible from simple precursors. It is known that cetyl ammonium bromide (CTAB) forms organic solvent-stable surfactant-assembled lipophilic nanoreactors.³ Addition of polyvalent iodine reagents onto electron-rich π -systems was found to be suitable for the current investigation since various iodobenzene dicarboxylates react with electron-rich π -systems.⁴ Earlier studies showed that indenenes can be regioselectively functionalized using $\text{PhI}(\text{OAc})_2$ in CTAB derived nano-reactors.⁵


Easily available glycals possess an electron-rich π -bond, and the utility of hypervalent iodine (I^{III}) reagents on glycals was studied for the selective C3-O-oxidation, C-2 heteroatom substitution, and oxidative glycosidation.^{6,7} In this premise, regioselective iodination of glycals has been hypothesized through surfactant-assembled structures by using CTAB and polycordinated iodine reagents for the synthesis of 2-deoxy-2-iodo acetates. Notably, 2-deoxy-2-iodo glycopyranosyl acetates are important precursors for the synthesis of 2-deoxy-, 2-alkyl, and 2-amino glycosides. Biological significance and their versatility coupled with the challenge of synthesizing 2-deoxy-glycopyranosides⁷ had attracted many researchers to develop strategies for their synthesis utilizing hypervalent iodine reagent,^{7a-h} de novo,⁸ and dehydrative⁷ⁱ glycosidation. 2-Deoxy-glycopyranosides can be accessed through moderately stable C-2 triflates,⁹ or by the addition of electrophilic iodine in a poorly regioselective manner to the electron rich π -bond of

glycals.⁷ Therefore, we thought of studying the reaction of hypervalent iodination on glycals in the presence of CTAB-assembled self-assembled structures for the regioselective synthesis of 2-deoxy-glycosides.

RESULTS AND DISCUSSION

To begin our investigation, a CH_2Cl_2 solution of per-O-acetylated glucal **1a** at 0 °C was added to $\text{PhI}(\text{OAc})_2$, CTAB, and KI. The resulting turbid solution was stirred at room temperature for 6 h to observe the formation of two inseparable products **2a** and **3a** in a 95:5 ratio which were characterized by NMR and MS analysis (Scheme 1);¹⁰ importantly, no regioisomeric mixture was noticed. The origin of selectivity is attributed to the micellar environment as postulated earlier.^{5,10} The formation of compound **3a** is possible due to the halide counterion exchange between CTAB and KI which was confirmed through a control


Scheme 1. Synthesis of C-2 Deoxy C-2 Iodo Anomeric Acetates in Self Assembled Structures



Received: February 26, 2014

Published: April 22, 2014

Scheme 2. Hypervalent Iodine for the Synthesis of C-2 Deoxy-2-iodo Anomeric Esters



experiment wherein KBr was added in place of KI to observe compound **3a** only (Scheme 1).

A regioisomeric mixture of products was noticed in the absence of CTAB. In addition, it is desirable to maintain the CTAB concentration at a critical micellar concentration (CMC) at 10 mol % for 15 mL in order to obtain self-assembled structures;^{5a,10} otherwise, a regioisomeric mixture of iodoacetates is observed. Both iodo- (**2a**) and bromo- (**3a**) saccharides can be subjected to the $\text{Bu}_3\text{SnH/AIBN}$ reaction to obtain corresponding *2-deoxy* derivatives.¹¹ Furthermore, anomeric esters are important as they can be easily activated by the addition of Lewis acids to obtain a variety of glycosides. A similar reaction between per-*O*-acetyl galactal and $\text{PhI}(\text{OAc})_2$ in CTAB and KI gave corresponding iodo acetate **2b** and bromo acetate **3b** with a 94:5 ratio of **2b**:**3b** (Scheme 1). Acetyl groups of the iodobenzene diacetate can be exchanged with carboxylic acids by slow evaporation of a solution of an equimolar mixture of $\text{PhI}(\text{OAc})_2$ and carboxylic acid (**4a–4h**) in chlorobenzene around 50 °C over 1 h.¹² The exchange reaction worked well, and various $\text{PhI}(\text{OCOR})_2$ compounds (**5a–5h**) were synthesized. Further, the generality of the regioselective halo ester glycoside synthesis was investigated with hypervalent iodine esters **5a–5h**.

Gratifyingly, the formation of iodo ester glycosides in very good yield along with a minor amount of bromo esters was noticed. For example, the reaction between glucal and iodo esters **5a–h** gave *2-deoxy*-glycosyl esters **6a–h** in very good yields (Scheme 2).¹⁰ Similar products in good yields were noticed with galactal (**1b**) and lactal (**1c**) to give products **7a–d** and **8a–e** in good yields with selected phenyl iodoesters (Scheme 2). Good quality crystals of compound **6e** could be obtained by slow evaporation from ethyl acetate and light petroleum (60–80 °C) and was subjected to X-ray structure determination.^{10,13} The crystal structure of compound **6e**

confirmed the presence of an iodo group in the manno-configuration and α -configured ester moiety.^{10,13}

Amino acid glycoconjugates are interesting since they can be easily converted to *N*-carboxy anhydrides (NCAs) for the synthesis of glycopolypeptides by ring-opening polymerization with amines in the presence of proton sponge.¹⁴ Additionally, amino acid glycoconjugates **6g**, **6h**, **7c**, **7d**, **8d**, and **8e** are correctly positioned to undergo intramolecular glycosidation in the presence of a suitable Lewis acid. The activator not only is able to cleave the silyl ether to give **A**, but also can perform as a Lewis acid to facilitate the departure of the anomeric ester. The resulting intermediate can further be attacked by the nucleophile in an intramolecular fashion to result in acid **B** (Figure 1). Subsequently, radical deiodination should give access to *2-deoxy* glycosides.





Figure 1. Rationale for the intramolecular aglycon delivery.

The biological significance of many natural products was found to be dependent on the presence of *2-deoxy* glycosides.¹⁵ However, the stereoselective synthesis of *2-deoxy* glycosides is still a challenge due to the absence of any directing group at the C-2 position.¹⁶ It is interesting to observe that NIS mediated amino acid glycoconjugate synthesis from glycals results^{16a} in the *2-iodo* α -glycosides whereas the current protocol gives access to β -glycosides in a stereoselective fashion.

Scheme 3. Synthesis of C-2 Iodo Amino Acid Glycosides



After several experiments with amino acid glycoconjugate **6g**, a catalytic amount of TMSOTf in CH_2Cl_2 at -78°C was found to be suitable for this transformation (Scheme 3). Initially, cleavage¹⁷ of silyl ether was noticed by TLC-MS analysis that subsequently was converted to C-2-iodo serinyl glycoside as a carboxylic acid in a very good yield; the acid was easily purified by converting it to the corresponding methyl ester **9a** under EDCI/DMAP/MeOH conditions (Scheme 3). Similar results were also observed with the threonine derivative **6h** to obtain **9b** in good yield. In addition, galacto-derived serine and threonine anomeric esters **7c** and **7d** also underwent the intramolecular glycosidation to give β -galactosyl amino acid glycoconjugates **11a** and **11b**. Compounds **9a–b** and **11a–b** were successfully subjected to radical mediated deiodination¹¹ using Bu_3SnH and AIBN in toluene at 120°C to obtain 2-deoxy β -glycosides **10a–b** and **12a–b** which are otherwise fairly difficult to synthesize in a stereoselective manner.

CONCLUSIONS

We have identified a practical, efficient, simple, and fully stereoselective method for the synthesis of 2-deoxy-2-iodo glycosides in self-assembled structures. Various 2-iodo glycosyl esters were synthesized in a stereoselective fashion. Intramolecular glycosidation of anomeric serinyl esters afforded β -serinyl glycosides, and the radical mediated deiodination at C-2 position resulted in 2-deoxy serinyl glycosides. Further investigation on the utilization of 2-deoxy serinyl glycosides for the synthesis of glycopolypeptides and other materials is currently underway.

EXPERIMENTAL SECTION

General Methods. Unless otherwise noted, materials were obtained from commercial suppliers and were used without further purification. Unless otherwise reported all reactions were performed under an argon atmosphere. Removal of solvent *in vacuo* refers to distillation using a rotary evaporator attached to an efficient vacuum pump. Products obtained as solids or syrups were dried under high vacuum. Analytical thin-layer chromatography was performed on precoated silica plates (F_{254} , 0.25 mm thickness); compounds were visualized by UV light or by staining with anisaldehyde spray. Optical rotations were measured on a polarimeter. IR spectra were recorded on an FT-IR spectrometer. NMR spectra were recorded on either a 400 or 500 MHz spectrometer with CDCl_3 as the solvent and TMS as the internal standard. High resolution mass spectroscopy (HRMS) was performed using a TOF mass analyzer. Low resolution mass spectroscopy (LRMS) was performed on UPLC-MS.

Procedure for the Synthesis of Compounds 2a. A two-neck round-bottom flask containing glucal (0.272 g, 1.0 mmol), anhydrous MgSO_4 (0.5 g), and CH_2Cl_2 (15 mL) at 0°C was added to $\text{PhI}(\text{OCOCH}_3)_2$ (0.644 g, 2.0 mmol), CTAB (0.039 g, 10 mol %), and KI (0.166 g, 1.0 mmol). The reaction mixture was stirred at 25°C for 6 h and diluted with water and extracted with CH_2Cl_2 (3×25 mL), and the combined organic portions were washed with aq. sodium bicarbonate and brine solution (2×10 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The resulting crude residue was purified by silica gel column chromatography using ethyl acetate and light petroleum ether (bp $60\text{--}70^\circ\text{C}$) to obtain compound **2a** (0.389 g, 85%) as a colorless thick syrup. The same general procedure was adopted for synthesizing compounds **2a–2c**, **3a**, **6a–6h**, **7a–7d**, and **8a–8e**.

Synthesis of Compound 9a. To C-2 deoxy 2-iodo amino acid glycoconjugate **6g** (0.750 g, 1.00 mmol) in CH_2Cl_2 (10 mL) was added 4 Å molecular sieves powder (0.5 g) at room temperature. After stirring for 30 min, the reaction mixture was cooled to -78°C and TMSOTf (45 μL , 0.25 mmol) was added and stirred for 30 min. The reaction mixture was slowly warmed to 0°C and stirred for 3 h, diluted with CH_2Cl_2 , and filtered through Celite. The filtrate was subsequently neutralized with excess triethylamine and concentrated *in vacuo*, and the residue was purified by silica gel column chromatography to give 2-iodo acid which was directly used for esterification. 2-Iodo acid (0.637 g, 1.00 mmol) was redissolved in CH_2Cl_2 (10 mL), and MeOH (61 μL , 1.5 mmol) was added followed by cooling to 0°C . 1-(3-(Dimethylamino)propyl)-3-ethyl carbodiimide (EDCI) (0.249 g, 1.30 mmol), Et_3N (181 μL , 1.30 mmol), and DMAP (0.030 g, 0.25 mmol) were added and stirred for 20 h at 25°C . The reaction was quenched with water and extracted with CH_2Cl_2 (2×25 mL). The combined organic layers were washed with saturated NaHCO_3 , water, and brine, dried, and concentrated *in vacuo* to obtain a residue that was purified by silica gel column chromatography using EtOAc and light petroleum (bp $60\text{--}70^\circ\text{C}$) to afford compound **9a** (0.485 g, 76%) as a colorless thick syrup. The same general procedure was adopted for synthesizing compounds **9b** and **11a–11b**.

Compound 2a. This compound is prepared using the above-mentioned general procedure using **1a** (0.272 g, 1 mmol) as the starting material. Yield: (0.389 g, 85%); $[\alpha]_D^{25} = +31.2$ ($c = 1.0$, CHCl_3); $^1\text{H NMR}$ (399.78 MHz, CDCl_3) δ 2.07 (s, 3 H), 2.11 (s, 3 H), 2.12 (s, 3 H), 2.17 (s, 3 H), 4.11 (ddd, 1H, $J = 7.4, 4.9$ Hz), 4.16 (dd, 1H, $J = 12.3, 4.4$ Hz), 4.23 (dd, 1H, $J = 12.3, 4.4$ Hz), 4.53 (dd, 1H, $J = 4.3, 1.5$ Hz), 4.59 (dd, 1H, $J = 9.5, 4.4$ Hz), 5.46 (t, 1H, $J = 9.6$ Hz), 6.39 (s, 1H); $^{13}\text{C NMR}$ (100.53 MHz, CDCl_3) δ 20.6, 20.7, 20.9, 20.9, 27.1, 61.8, 67.0, 68.6, 71.4, 94.7, 168.2, 169.3, 169.9, 170.7; IR (CHCl_3) ν 2925, 1747, 1216, 1048 cm^{-1} ; HRMS (TOF) m/z [$M + \text{Na}$] $^+$ calcd for $\text{C}_{14}\text{H}_{19}\text{INaO}_9$, 480.9971, found 480.9979.

Compound 2b. This compound is prepared using the above-mentioned general procedure using **1b** (0.272 g, 1 mmol) as the starting material. Yield: (0.367 g, 80%); $[\alpha]_D^{25} = +43.2$ ($c = 1.0$,

CHCl₃); ¹H NMR (399.78 MHz, CDCl₃) δ 1.98 (s, 3H), 2.03 (s, 3H), 2.08 (s, 3H), 2.13 (s, 3H), 4.12 (d, 2H, *J* = 6.6 Hz), 4.20–4.23 (m, 1H), 4.34 (td, 1H, *J* = 6.7, 1.9 Hz), 4.83 (t, 1H), 5.35–5.39 (m, 1H), 6.44 (d, 1H); ¹³C NMR (100.53 MHz, CDCl₃) δ 18.8, 20.6, 20.8, 20.9, 28.9, 61.4, 64.7, 64.8, 69.0, 96.0, 168.2, 169.6, 170.0, 170.4; IR (CHCl₃) ν 2925, 1745, 1219, 1143 cm⁻¹; HRMS (TOF) *m/z* [M + Na]⁺ calcd for C₁₄H₁₉INaO, 480.9971, found 480.9979.

Compound 2c. This compound is prepared using the above-mentioned general procedure using **1c** (0.560 g, 1 mmol) as the starting material. Yield: (0.560 g, 75%); [α]_D = +17.0 (*c* = 1.0, CHCl₃); ¹H NMR (399.78 MHz, CDCl₃) δ 1.98 (s, 3H), 2.07 (s, 9H), 2.14 (s, 3H), 2.16 (s, 3H), 2.17 (s, 3H), 3.91–3.96 (m, 1H), 4.07 (dd, 1H, *J* = 11.1, 6.9 Hz), 4.19 (m, 4H), 4.54 (dd, 1H, *J* = 12.1, 1.8 Hz), 4.60 (d, 1H, *J* = 7.9 Hz), 4.71 (dd, 1H, *J* = 3.9, 1.6 Hz), 5.00 (dd, 1H, *J* = 10.4, 3.5 Hz), 5.17 (dd, 1H, *J* = 10.4, 8.0 Hz), 5.36–5.38 (m, 1H), 5.43 (dd, 1H, *J* = 8.9, 3.9 Hz), 6.22 (d, 1H, *J* = 1.3 Hz); ¹³C NMR (100.53 MHz, CDCl₃) δ 20.5, 20.6 (4C), 20.8, 20.8, 22.6, 52.1, 61.1, 61.2, 66.7, 68.3, 69.1, 70.7, 70.9, 72.5, 73.4, 90.7, 101.2, 169.2, 169.4, 170.1, 170.1, 170.1, 170.1, 170.3, 170.4; IR (CHCl₃) ν 2930, 1746, 1221, 1053 cm⁻¹; HRMS (TOF) *m/z* [M + Na]⁺ calcd for C₂₆H₃₅INaO₁₇ 769.0817, found 769.0816.

Compound 3a. This compound is prepared using the above-mentioned general procedure using **1a** (0.272 g, 1 mmol) as the starting material. Yield: (0.292 g, 71%); [α]_D = +31.0 (*c* = 1.0, CHCl₃); ¹H NMR (399.78 MHz, CDCl₃) δ 2.07 (s, 3H), 2.11 (s, 6H), 2.18 (s, 3H), 4.11 (ddd, 1H, *J* = 10.0, 4.5, 2.5 Hz), 4.15 (dd, 1H, *J* = 12.4, 2.4 Hz), 4.24 (dd, 1H, *J* = 12.4, 4.5 Hz), 4.44 (dd, 1H, *J* = 3.9, 1.7 Hz), 5.20 (dd, 1H, *J* = 9.7, 4.0 Hz), 5.49 (t, 1H, *J* = 9.8 Hz), 6.32 (d, 1H, *J* = 1.5 Hz); ¹³C NMR (100.53 MHz, CDCl₃) δ 20.5, 20.6, 20.7, 20.8, 47.8, 61.8, 65.5, 68.7, 71.2, 93.1, 168.0, 169.2, 170.0, 170.6; IR (CHCl₃) ν 2925, 1745, 1219, 1143 cm⁻¹; HRMS (TOF) *m/z* [M + Na]⁺ calcd for C₁₄H₁₉BrNaO, 433.0110, 435.0090, found 433.0078, 435.0087.

Compound 6a. This compound is prepared using the above-mentioned general procedure using **1a** (0.272 g, 1 mmol) as the starting material. Yield: (0.356 g, 76%); [α]_D = +61.0 (*c* = 1.0, CHCl₃); ¹H NMR (399.78 MHz, CDCl₃) δ 2.08 (s, 3H), 2.12 (s, 3H), 2.12 (s, 3H), 3.07 (s, 1H), 4.13–4.19 (m, 2H), 4.24 (dd, 1H, *J* = 12.7, 4.8 Hz), 4.59 (bs, 1H), 4.60 (d, 1H, *J* = 6.0 Hz), 5.41–5.53 (m, 1H), 6.47 (s, 1H); ¹³C NMR (100.53 MHz, CDCl₃) δ 20.6, 20.7, 20.9, 26.2, 61.6, 66.7, 68.4, 71.8, 73.3, 77.1, 96.0, 149.7, 169.3, 169.8, 170.6; IR (CHCl₃) ν 3258, 2950, 1741, 1145, 1059 cm⁻¹; HRMS (TOF) *m/z* [M + Na]⁺ calcd for C₁₅H₁₉INaO, 490.9815, found 490.9825.

Compound 6b. This compound is prepared using the above-mentioned general procedure using **1a** (0.272 g, 1 mmol) as the starting material. Yield: (0.437 g, 73%); [α]_D = +25.8 (*c* = 1.0, CHCl₃); ¹H NMR (399.78 MHz, CDCl₃) δ 0.82–0.92 (m, 3H), 1.21–1.37 (m, 16H), 1.65 (q, 2H, *J* = 7.3 Hz), 2.07 (s, 3H), 2.11 (s, 3H), 2.11 (s, 3H), 2.40 (t, 1H, *J* = 7.5 Hz), 4.11 (ddd, 1H, *J* = 9.9, 4.6, 2.5 Hz), 4.15 (dd, 1H, *J* = 12.4, 2.4 Hz), 4.22 (dd, 1H, *J* = 12.3, 4.6 Hz), 4.53 (dd, 1H, *J* = 4.4, 1.6 Hz), 4.58 (dd, 1H, *J* = 9.4, 4.4 Hz), 5.45 (t, 1H, *J* = 9.7 Hz), 6.40 (d, 1H, *J* = 1.4 Hz); ¹³C NMR (100.53 MHz, CDCl₃) δ 14.0, 20.5, 20.6, 20.7, 22.5, 24.6, 27.2, 28.8, 29.1, 29.2, 29.3, 29.4(2C), 31.8, 33.9, 61.7, 66.9, 68.6, 71.3, 94.3, 169.2, 169.7, 170.5, 170.8; IR (CHCl₃) ν 2932, 1745, 1132, 1045 cm⁻¹; HRMS (TOF) *m/z* [M + Na]⁺ calcd for C₂₄H₃₉INaO, 621.1536, found 621.1547.

Compound 6c. This compound is prepared using the above-mentioned general procedure using **1a** (0.272 g, 1 mmol) as the starting material. Yield: (0.517 g, 80%); [α]_D = +27.6 (*c* = 1.0, CHCl₃); ¹H NMR (399.78 MHz, CDCl₃) δ 2.07 (s, 3H), 2.12 (s, 3H), 2.12 (s, 3H), 4.14–4.33 (m, 3H), 4.75 (d, 1H, *J* = 2.1 Hz), 4.78 (d, 1H, *J* = 4.5 Hz), 5.47–5.59 (m, 1H), 6.67 (s, 1H), 7.22 (td, 1H, *J* = 7.6, 1.7 Hz), 7.47 (td, 1H, *J* = 7.6, 1.1 Hz), 7.83 (dd, 1H, *J* = 7.8, 1.6 Hz), 8.04 (dd, 1H, *J* = 7.9, 1.0 Hz); ¹³C NMR (100.53 MHz, CDCl₃) δ 20.6, 20.8, 20.9, 27.0, 61.8, 66.9, 68.8, 72.0, 93.9, 96.1, 128.2, 131.6, 133.4, 133.5, 141.6, 163.9, 169.3, 169.9, 170.7; IR (CHCl₃) ν 3013, 2931, 1746, 1551, 1441, 1121, 1033, 661 cm⁻¹; HRMS (TOF) *m/z* [M + Na]⁺ calcd for C₁₉H₂₀I₂NaO, 668.9094, found 668.9141.

Compound 6d. This compound is prepared using the above-mentioned general procedure using **1a** (0.272 g, 1 mmol) as the

starting material. Yield: (0.447 g, 72%); [α]_D = +19.9 (*c* = 1.0, CHCl₃); ¹H NMR (399.78 MHz, CDCl₃) δ 2.06 (s, 3H), 2.10 (s, 6H), 2.67 (t, 2H, *J* = 5.8 Hz), 3.51 (q, 2H, *J* = 6.0 Hz), 4.07–4.18 (m, 2H), 4.21 (dd, 1H, *J* = 12.4, 4.4 Hz), 4.52–4.58 (m, 2H), 5.10 (s, 2H), 5.36 (t, 1H, *J* = 6.1 Hz), 5.46 (t, 1H, *J* = 9.4 Hz), 6.41 (s, 1H), 7.35 (m, 5H); ¹³C NMR (100.53 MHz, CDCl₃) δ 20.6, 20.7, 20.9, 26.9, 34.3, 36.4, 61.7, 66.8(2C), 68.6, 71.5, 94.9, 128.0–128.5 (5C), 136.2, 156.3, 169.3, 169.8, 169.9, 170.7; IR (CHCl₃) ν 3396, 3051, 2958, 1742, 1520, 1130, 1005 cm⁻¹; HRMS (TOF) *m/z* [M + Na]⁺ calcd for C₂₃H₂₈INNaO₁₁ 644.0605, found 644.0597.

Compound 6e. This compound is prepared using the above-mentioned general procedure using **1a** (0.272 g, 1 mmol) as the starting material. Yield: (0.470 g, 80%); mp: 131 °C; [α]_D = +7.80 (*c* = 1.0, CHCl₃); ¹H NMR (399.78 MHz, CDCl₃) δ 1.45 (s, 9H), 1.46 (s, 3H), 2.08 (s, 3H), 2.11 (s, 3H), 2.12 (s, 3H), 4.16 (dd, 2H, *J* = 14.0, 11.1 Hz), 4.24 (dd, 1H, *J* = 12.0, 4.0 Hz), 4.31–4.40 (m, 1H), 4.51–4.60 (m, 2H), 5.02 (d, 1H, *J* = 7.1 Hz), 5.48 (t, 1H, *J* = 9.4 Hz), 6.40 (s, 1H); ¹³C NMR (100.53 MHz, CDCl₃) δ 18.1, 21.0, 20.7, 20.9, 26.7, 28.2 (3C), 49.0, 61.6, 66.7, 68.7, 71.6, 80.2, 95.5, 155.0, 169.3, 169.8, 170.7, 171.1; IR (CHCl₃) ν 3384, 2981, 1747, 1515, 1454, 1160, 1057, 666 cm⁻¹; HRMS (TOF) *m/z* [M + Na]⁺ calcd for [C₂₀H₃₀INNaO₁₁ 610.0761, found 610.0770.

Compound 6f. This compound is prepared using the above-mentioned general procedure using **1a** (0.272 g, 1 mmol) as the starting material. Yield: (0.550 g, 81%); [α]_D = +40.0 (*c* = 1.0, CHCl₃); ¹H NMR (399.78 MHz, CDCl₃) δ 1.45 (s, 9H), 2.08 (s, 3H), 2.11 (s, 3H), 2.12 (s, 3H), 2.93–3.04 (m, 2H), 3.79 (s, 3H), 4.10–4.19 (m, 2H), 4.23 (dd, 1H, *J* = 12.3, 4.4 Hz), 4.53 (dd, 1H, *J* = 9.5, 4.4 Hz), 4.57–4.66 (m, 2H), 5.46 (t, 1H, *J* = 9.7 Hz), 5.58 (d, 1H, *J* = 8.0 Hz), 6.38 (s, 1H); ¹³C NMR (100.53 MHz, CDCl₃) δ 20.5, 20.6, 20.8, 26.8, 28.2 (3C), 36.9, 49.9, 52.8, 61.6, 66.8, 68.5, 71.6, 80.3, 95.3, 155.1, 168.4, 169.2, 169.7, 170.6, 171.0; IR (CHCl₃) ν 3374, 2977, 1745, 1510, 1438, 1162, 1056, 669 cm⁻¹; HRMS (TOF) *m/z* [M + Na]⁺ calcd for C₂₂H₃₂INNaO₁₃ 668.0816, found 668.0789.

Compound 6g. This compound is prepared using the above-mentioned general procedure using **1a** (0.272 g, 1 mmol) as the starting material. Yield: (0.603 g, 81%); [α]_D = +8.0 (*c* = 1.0, CHCl₃); ¹H NMR (399.78 MHz, CDCl₃) δ 0.03 (s, 3H), 0.04 (s, 3H), 0.85 (s, 9H), 2.05 (s, 3H), 2.09 (s, 3H), 2.11 (s, 3H), 3.88 (dd, 1H, *J* = 10.3, 3.1 Hz), 4.08–4.11 (m, 2H), 4.11–4.14 (m, 1H), 4.23 (dd, 1H, *J* = 12.5, 4.3 Hz), 4.46–4.49 (m, 1H), 4.50 (dd, 1H, *J* = 4.4, 1.5 Hz), 4.58 (dd, 1H, *J* = 9.5, 4.4 Hz), 5.15 (d, 2H, *J* = 10.9 Hz), 5.46 (t, 1H, *J* = 9.8 Hz), 5.58 (d, 1H, *J* = 8.5 Hz), 6.42 (s, 1H), 7.32–7.39 (m, 5H); ¹³C NMR (100.53 MHz, CDCl₃) δ -5.7, -5.6, 18.2, 20.6, 20.7, 20.8, 25.7 (3C), 26.6, 56.0, 62.0, 63.4, 66.8, 67.3, 68.4, 71.6, 95.6, 128.2–128.6 (5C), 136.0, 155.9, 168.1, 169.3, 170.0, 170.7; IR (CHCl₃) ν 3365, 2934, 1747, 1512, 1427, 1117, 1056, 668 cm⁻¹; HRMS (TOF) *m/z* [M + Na]⁺ calcd for C₂₉H₄₂INNaO₁₂Si 774.1419, found 774.1423.

Compound 6h. This compound is prepared using the above-mentioned general procedure using **1a** (0.272 g, 1 mmol) as the starting material. Yield: (0.605 g, 79%); [α]_D = +5.4 (*c* = 1.0, CHCl₃); ¹H NMR (399.78 MHz, CDCl₃) δ 0.00 (s, 3H), 0.05 (s, 3H), 0.82 (s, 9H), 1.24 (d, 3H, *J* = 6.2 Hz), 2.03 (s, 3H), 2.09 (s, 6H), 3.98–4.14 (m, 2H), 4.22 (dd, 1H, *J* = 12.8, 4.3 Hz), 4.31 (dd, 1H, *J* = 9.3, 1.7 Hz), 4.40–4.62 (m, 3H), 5.16 (d, 2H, *J* = 6.6 Hz), 5.46 (t, 2H, *J* = 9.2 Hz), 6.39 (s, 1H), 7.29–7.41 (m, 5H); ¹³C NMR (100.53 MHz, CDCl₃) δ -5.4, -4.4, 17.8, 20.5, 20.6, 20.7, 20.8, 25.5(3C), 26.6, 60.0, 61.4, 66.6, 67.3, 68.4, 68.5, 71.5, 95.5, 128.2–128.5 (5C), 135.9, 156.5, 168.4, 169.2, 169.6, 171.0; IR (CHCl₃) ν 3445, 2955, 1744, 1512, 1426, 1136, 1063, 698 cm⁻¹; HRMS (TOF) *m/z* [M + Na]⁺ calcd for C₃₀H₄₄INNaO₁₂Si 788.1575, found 788.1581.

Compound 7a. This compound is prepared using the above-mentioned general procedure using **1b** (0.272 g, 1 mmol) as the starting material. Yield: (0.472 g, 76%); [α]_D = +41.2 (*c* = 1.0, CHCl₃); ¹H NMR (399.78 MHz, CDCl₃) δ 2.01 (s, 3H), 2.08 (s, 3H), 2.18 (s, 3H), 2.51–2.69 (m, 2H), 3.48 (dt, 2H, *J* = 13.6, 6.4 Hz), 4.16 (d, 2H, *J* = 6.6 Hz), 4.30 (d, 1H, *J* = 4.6 Hz), 4.38 (t, 1H, *J* = 5.9 Hz), 4.84–4.88 (m, 1H), 5.08 (s, 2H), 5.40–5.42 (m, 2H), 6.52 (d, 1H, *J* = 1.2 Hz), 7.31–7.37 (m, 5H); ¹³C NMR (100.53 MHz, CDCl₃) δ 18.6, 20.5, 20.7, 20.8, 34.3, 36.3, 61.4, 64.6, 64.7, 66.7, 69.0, 96.1, 128.0–

128.4 (5C), 136.1, 156.2, 169.4, 169.7, 169.9, 170.4; IR (CHCl₃) ν 3383, 2951, 1745, 1519, 1427, 1130, 1059, 666 cm⁻¹; HRMS (TOF) m/z [M + Na]⁺ calcd for C₂₃H₂₈INNaO₁₁ 644.0605, found 644.0617.

Compound 7b. This compound is prepared using the above-mentioned general procedure using **1b** (0.272 g, 1 mmol) as the starting material. Yield: (0.487 g, 83%); [α]_D = +22.4 (*c* = 1.0, CHCl₃); ¹H NMR (399.78 MHz, CDCl₃) δ 1.42 (s, 3H), 1.44 (s, 9H), 2.05 (s, 3H), 2.09 (s, 3H), 2.19 (s, 3H), 4.12–4.25 (m, 2H), 4.31 (d, 2H, *J* = 4.3 Hz), 4.47 (t, 1H, *J* = 6.1 Hz), 4.86–4.91 (m, 1H), 5.20 (m, 1H, *J* = 7.3 Hz), 5.45 (s, 1H), 6.52 (s, 1H); ¹³C NMR (100.53 MHz, CDCl₃) δ 17.7, 18.5, 20.5, 20.6, 20.7, 28.1 (3C), 49.0, 61.2, 64.6 (2C), 69.0, 79.9, 96.5, 154.9, 169.2, 169.7, 170.2, 170.8; IR (CHCl₃) ν 3372, 2980, 1748, 1515, 1427, 1166, 1060, 670 cm⁻¹; HRMS (TOF) m/z [M + Na]⁺ calcd for C₂₀H₃₀INNaO₁₁ 610.0761, found 610.0771.

Compound 7c. This compound is prepared using the above-mentioned general procedure using **1b** (0.272 g, 1 mmol) as the starting material. Yield: (0.556 g, 74%); [α]_D = +20.6 (*c* = 1.0, CHCl₃); ¹H NMR (399.78 MHz, CDCl₃) δ -0.07 (s, 3H), -0.05 (s, 3H), 0.76 (s, 9H), 1.94 (s, 3H), 1.99 (s, 3H), 2.10 (s, 3H), 3.79 (dd, 1H, *J* = 10.3, 3.1 Hz), 3.99 (dd, 1H, *J* = 10.3, 2.7 Hz), 4.07 (dd, 1H, *J* = 15.6, 6.6 Hz), 4.16 (d, 1H, *J* = 4.9 Hz), 4.25–4.32 (m, 1H), 4.38 (dt, 1H, *J* = 8.3, 2.8 Hz), 4.71–4.79 (m, 1H), 5.05 (d, 2H, *J* = 4.4 Hz), 5.34 (s, 1H), 5.52 (d, 1H, *J* = 8.4 Hz), 6.46 (s, 2H), 7.24–7.30 (m, 5H); ¹³C NMR (100.53 MHz, CDCl₃) δ -5.7, -3.7, 18.0, 18.0, 20.5, 20.7, 20.9, 25.6 (3C), 25.7, 61.3, 63.3, 64.5, 64.6, 67.2, 69.3, 97.2, 128.2–128.5 (5C), 136.0, 155.9, 168.1, 169.3, 170.0, 170.3; IR (CHCl₃) ν 3367, 2953, 1748, 1513, 1464, 1130, 1058, 670 cm⁻¹; HRMS (TOF) m/z [M + Na]⁺ calcd for C₂₉H₄₂INNaO₁₂Si 774.1419, found 774.1425.

Compound 7d. This compound is prepared using the above-mentioned general procedure using **1b** (0.272 g, 1 mmol) as the starting material. Yield: (0.689 g, 90%); [α]_D = +29.4 (*c* = 1.0, CHCl₃); ¹H NMR (399.78 MHz, CDCl₃) δ -0.05 (s, 3H), 0.00 (s, 3H), 0.78 (s, 9H), 1.20 (d, 3H, *J* = 6.2 Hz), 1.97 (s, 3H), 2.04 (s, 3H), 2.13 (s, 3H), 4.00–4.07 (m, 1H), 4.12 (ddd, 1H, *J* = 11.3, 6.5, 1.4 Hz), 4.20–4.25 (m, 2H), 4.28 (t, 1H, *J* = 6.6 Hz), 4.35–4.43 (m, 1H), 4.77 (t, 1H, *J* = 3.5 Hz), 5.08–5.16 (m, 2H), 5.36 (s, 1H), 5.41 (d, 1H, *J* = 8.9 Hz), 6.47 (s, 1H), 7.25–7.39 (m, 5H); ¹³C NMR (100.53 MHz, CDCl₃) δ -5.4, -4.3, 17.8, 18.1, 20.6, 20.8, 20.9, 20.9, 25.5 (3C), 60.0, 61.3, 64.5, 64.6, 67.3, 68.4, 69.3, 97.3, 128.3, 128.6, 136.0, 156.6, 168.6, 169.3, 169.9, 170.3; IR (CHCl₃) ν 3446, 2934, 1749, 1511, 1426, 1136, 1067, 699 cm⁻¹; HRMS (TOF) m/z [M + Na]⁺ calcd for C₃₀H₄₄INNaO₁₂Si 788.1575, found 788.1572.

Compound 8a. This compound is prepared using the above-mentioned general procedure using **1c** (0.560 g, 1 mmol) as the starting material. Yield: (0.691 g, 76%); [α]_D = +31.5 (*c* = 1.0, CHCl₃); ¹H NMR (399.78 MHz, CDCl₃) δ 1.98 (s, 3H), 2.06 (s, 3H), 2.07 (s, 3H), 2.12 (s, 3H), 2.15 (s, 3H), 2.16 (s, 3H), 2.65 (t, 2H, *J* = 5.8 Hz), 3.50 (q, 2H, *J* = 5.9 Hz), 3.92–3.98 (m, 1H), 3.99–4.14 (m, 4H), 4.18 (dd, 1H, *J* = 11.3, 6.8 Hz), 4.43 (dd, 1H, *J* = 12.1, 1.7 Hz), 4.49–4.54 (m, 1H), 4.61 (d, 1H, *J* = 8.0 Hz), 4.67 (dd, 1H, *J* = 7.2, 4.1 Hz), 5.00 (dd, 1H, *J* = 10.5, 3.5 Hz), 5.10 (s, 2H), 5.16 (dd, 1H, *J* = 10.4, 7.9 Hz), 5.30 (t, 1H, *J* = 6.0 Hz), 5.36–5.40 (m, 1H), 6.35 (d, 1H, *J* = 2.5 Hz), 7.32–7.38 (m, 5H); ¹³C NMR (100.53 MHz, CDCl₃) δ 20.5, 20.6 (2C), 20.7, 20.8, 21.0, 26.9, 34.4, 36.4, 61.1, 61.7, 66.7, 66.8, 69.0, 69.4, 70.7, 70.9, 71.8, 75.4, 94.7, 101.4, 128.1–128.5 (5C), 136.3, 156.2, 169.3, 169.5, 170.0, 170.1 (2C), 170.4 (2C); IR (CHCl₃) ν 3378, 2929, 1747, 1516, 1461, 1133, 1076, 668 cm⁻¹; HRMS (TOF) m/z [M + Na]⁺ calcd for C₃₅H₄₄INNaO₁₉ 932.1449, found 932.1443.

Compound 8b. This compound is prepared using the above-mentioned general procedure using **1c** (0.560 g, 1 mmol) as the starting material. Yield: (0.727 g, 83%); [α]_D = +25.8 (*c* = 1.0, CHCl₃); ¹H NMR (399.78 MHz, CDCl₃) δ 1.44 (s, 9H), 1.98 (s, 3H), 2.03 (s, 3H), 2.08 (d, 6H, *J* = 1.1 Hz), 2.14 (s, 3H), 2.15 (s, 3H), 2.17 (s, 3H), 3.99 (t, 1H, *J* = 6.6 Hz), 4.05–4.13 (m, 3H), 4.14–4.21 (m, 2H), 4.29–4.36 (m, 1H), 4.43 (d, 1H, *J* = 11.8 Hz), 4.50–4.55 (m, 1H), 4.64 (d, 1H, *J* = 7.9 Hz), 4.68 (s, 1H), 5.02 (dd, 1H, *J* = 0.4, 3.3 Hz), 5.15 (dd, 1H, *J* = 10.4, 8.1 Hz), 5.23 (d, 1H, *J* = 7.1 Hz), 5.38 (d, 1H, *J* = 3.4 Hz), 6.35 (s, 1H); ¹³C NMR (100.53 MHz, CDCl₃) δ 17.7, 20.2, 20.3 (2C), 20.4, 20.5, 20.7, 26.7, 28.0 (3C), 48.9, 61.0, 61.4, 66.6,

68.8, 69.1, 70.4, 70.6, 71.6, 75.0, 80.0, 95.0, 101.1, 154.8, 169.0, 169.2, 169.7, 169.8, 170.1 (2C), 171.1; IR (CHCl₃) ν 3382, 2981, 1747, 1514, 1453, 1164, 1053, 666 cm⁻¹; HRMS (TOF) m/z [M + Na]⁺ calcd for C₃₂H₄₆INNaO₁₉ 898.1606, found 898.1613.

Compound 8c. This compound is prepared using the above-mentioned general procedure using **1c** (0.560 g, 1 mmol) as the starting material. Yield: (0.774 g, 80%); [α]_D = +35.4 (*c* = 1.0, CHCl₃); ¹H NMR (399.78 MHz, CDCl₃) δ 1.45 (s, 9H), 1.98 (s, 3H), 2.08 (s, 6H), 2.15 (s, 6H), 2.17 (s, 3H), 2.90–3.09 (m, 2H), 3.78 (s, 3H), 3.95 (t, 1H, *J* = 6.7 Hz), 4.01–4.15 (m, 4H), 4.18 (dd, 1H, *J* = 11.2, 6.7 Hz), 4.46 (dd, 1H, *J* = 12.0, 1.5 Hz), 4.54 (s, 1H), 4.61 (dd, 3H, *J* = 12.1, 7.4 Hz), 5.00 (dd, 1H, *J* = 10.4, 3.5 Hz), 5.15 (dd, 1H, *J* = 10.4, 7.9 Hz), 5.32–5.43 (m, 1H), 5.50 (d, 1H, *J* = 8.1 Hz), 6.33 (d, 1H, *J* = 2.0 Hz); ¹³C NMR (100.53 MHz, CDCl₃) δ 20.5, 20.6, 20.6, 20.7, 20.8, 20.9, 27.0, 28.2 (3C), 36.9, 49.9, 52.9, 61.1, 61.6, 66.8, 69.0, 69.1, 70.7, 70.9, 72.0, 75.2, 80.4, 95.2, 101.4, 155.2, 168.7, 169.3, 169.5, 170.0, 170.1, 170.4 (2C), 171.1; IR (CHCl₃) ν 3678, 2929, 1746, 1512, 1434, 1164, 1052, 756 cm⁻¹; HRMS (TOF) m/z [M + Na]⁺ calcd for C₃₄H₄₈INNaO₂₁ 956.1661, found 956.1667.

Compound 8d. This compound is prepared using the above-mentioned general procedure using **1c** (0.560 g, 1 mmol) as the starting material. Yield: (0.832 g, 80%); [α]_D = +18.0 (*c* = 1.0, CHCl₃); ¹H NMR (399.78 MHz, CDCl₃) δ 0.03 (s, 3H), 0.04 (s, 3H), 0.85 (s, 9H), 1.98 (s, 3H), 2.07 (s, 6H), 2.10–2.18 (m, 9H), 3.88 (dd, 1H, *J* = 10.4, 3.1 Hz), 3.94 (t, 1H, *J* = 6.7 Hz), 3.97–4.04 (m, 1H), 4.07 (m, 4H), 4.18 (dd, 1H, *J* = 11.2, 6.7 Hz), 4.41 (d, 1H, *J* = 13.6 Hz), 4.41–4.53 (m, 2H), 4.61 (d, 1H, *J* = 7.9 Hz), 4.72 (dd, 1H, *J* = 7.0, 4.1 Hz), 5.00 (dd, 1H, *J* = 10.4, 3.4 Hz), 5.06–5.23 (m, 3H), 5.37 (d, 1H, *J* = 3.2 Hz), 5.58 (d, 1H, *J* = 8.6 Hz), 6.39 (d, 1H, *J* = 2.4 Hz), 7.32–7.40 (m, 5H); ¹³C NMR (100.53 MHz, CDCl₃) δ -5.6, -5.6, -5.6, 18.1, 20.5, 20.6, 20.6, 20.7, 20.8, 20.9, 25.7 (3C), 26.5, 55.9, 61.1, 61.6, 63.3, 66.7, 67.2, 69.0, 69.3, 70.7, 70.9, 71.8, 75.4, 95.4, 101.4, 128.2–128.5 (5C), 136.1, 155.9, 168.3, 169.2, 169.2, 170.0, 170.1, 170.4 (2C); IR (CHCl₃) ν 3369, 2935, 1748, 1514, 1425, 1112, 1057, 699 cm⁻¹; HRMS (TOF) m/z [M + K]⁺ calcd for C₄₁H₅₈IKNO₂₀Si 1078.2003, found 1078.2015.

Compound 8e. This compound is prepared using the above-mentioned general procedure using **1c** (0.560 g, 1 mmol) as the starting material. Yield: (0.811 g, 77%); [α]_D = +13.0 (*c* = 1.0, CHCl₃); ¹H NMR (399.78 MHz, CDCl₃) δ -0.07 (s, 3H), -0.02 (s, 3H), 0.75 (s, 9H), 1.17 (d, 3H, *J* = 6.2 Hz), 1.89 (s, 3H), 1.99 (s, 6H), 2.02 (s, 3H), 2.05 (s, 3H), 2.07 (s, 3H), 3.85–3.95 (m, 2H), 3.96–4.05 (m, 2H), 4.09 (dd, 2H, *J* = 11.2, 6.8 Hz), 4.23 (dd, 1H, *J* = 9.4, 1.6 Hz), 4.35 (m, 2H), 4.46 (dd, 1H, *J* = 4.0, 2.2 Hz), 4.55 (d, 1H, *J* = 7.9 Hz), 4.59 (dd, 1H, *J* = 8.0, 4.8 Hz), 4.93 (dd, 1H, *J* = 10.4, 3.3 Hz), 5.00–5.14 (m, 3H), 5.29 (d, 1H, *J* = 3.3 Hz), 5.40 (d, 1H, *J* = 9.5 Hz), 6.29 (d, 1H, *J* = 1.9 Hz), 7.23–7.36 (m, 5H); ¹³C NMR (100.53 MHz, CDCl₃) δ -5.5, -4.4, 17.7, 20.4, 20.4, 20.5, 20.5, 20.5, 20.6, 20.7, 20.7, 25.4 (3C), 26.8, 59.8, 61.0, 61.4, 66.6, 67.2, 68.4, 68.9, 69.1, 70.5, 70.8, 71.7, 74.9, 95.2, 101.1, 128.1–128.4 (5C), 136.0, 156.4, 168.9, 169.1, 169.1, 169.9, 169.9, 170.2, 170.3; IR (CHCl₃) ν 3445, 2932, 1745, 1512, 1462, 1134, 1071, 698 cm⁻¹; HRMS (TOF) m/z [M + K]⁺ calcd for C₄₂H₆₀IKNO₂₀Si 1092.2160, found 1092.2193.

Compound 9a. This compound is prepared using the above-mentioned general procedure using **6g** (0.750 g, 1 mmol) as the starting material. Yield: (0.494 g, 76%); [α]_D = +40.7 (*c* = 1.0, CHCl₃); ¹H NMR (399.78 MHz, CDCl₃) δ 2.03 (s, 3H), 2.07 (s, 3H), 2.09 (s, 3H), 3.80 (s, 3H), 3.92–4.01 (m, 3H), 4.18 (dd, 1H, *J* = 12.3, 2.3 Hz), 4.18 (dd, 1H, *J* = 12.3, 5.0 Hz), 4.48 (dd, 1H, *J* = 4.3, 1.3 Hz), 4.54 (dt, 2H, *J* = 9.2, 5.6 Hz), 5.14 (d, 3H, *J* = 5.8 Hz), 5.31 (t, 1H, *J* = 9.6 Hz), 5.82 (d, 1H, *J* = 8.2 Hz), 7.31–7.39 (m, 5H); ¹³C NMR (100.53 MHz, CDCl₃) δ 20.5, 20.6, 20.8, 28.5, 52.8, 54.1, 61.9, 67.1, 68.7 (2C), 68.9, 69.6, 101.8, 128.0–128.4 (5C), 135.9, 155.7, 169.3, 169.6, 170.0, 170.5; IR (CHCl₃) ν 3378, 2930, 1742, 1519, 1452, 1123, 1051, 699 cm⁻¹; HRMS (TOF) m/z [M + Na]⁺ calcd for C₂₄H₃₀INNaO₁₂ 674.0710, found 674.0709.

Compound 9b. This compound is prepared using the above-mentioned general procedure using **6h** (0.750 g, 1 mmol) as the starting material. Yield: (0.485 g, 73%); [α]_D = +35.6 (*c* = 1.0, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 1.31 (d, 3H, *J* = 6.4 Hz), 2.05

(s, 3H), 2.07 (s, 3H), 2.09 (s, 3H), 3.78 (s, 3H), 4.06 (ddd, 1H, $J = 9.8, 5.2, 2.4$ Hz), 4.13 (dd, 1H, $J = 12.2, 2.3$ Hz), 4.20 (dd, 1H, $J = 12.2, 5.3$ Hz), 4.32–4.39 (m, 2H), 4.44 (dd, 1H, $J = 9.7, 2.3$ Hz), 4.53 (dd, 1H, $J = 9.3, 4.3$ Hz), 5.16 (d, 3H, $J = 9.4$ Hz), 5.31 (t, 1H, $J = 9.6$ Hz), 5.48 (d, 1H, $J = 9.6$ Hz), 7.30–7.44 (m, 5H); ^{13}C NMR (101 MHz, CDCl_3) δ 17.8, 20.6, 20.6, 20.9, 28.8, 52.7, 58.5, 62.2, 67.3, 67.5, 68.7, 69.7, 77.3, 102.6, 128.2–128.5 (5C), 135.9, 156.5, 169.4, 169.7, 170.6, 170.6; IR (CHCl_3) ν 3358, 2950, 1744, 1518, 1452, 1175, 1038, 643 cm^{-1} ; HRMS (TOF) m/z [$\text{M} + \text{Na}$] $^+$ calcd for $\text{C}_{25}\text{H}_{32}\text{INNaO}_{12}$ 688.0867, found 688.0861.

Compound 10a. This compound is prepared by the reported procedure¹¹ using **9a** (0.400 g, 0.6 mmol) as the starting material. Yield: (0.210 g, 65%); $[\alpha]_{\text{D}} = +48.6$ ($c = 1.0, \text{CHCl}_3$); ^1H NMR (399.78 MHz, CDCl_3) δ 1.73 (td, 1H, $J = 12.9, 3.7$ Hz), 1.93 (s, 3H), 1.95 (s, 3H), 2.00 (s, 3H), 2.13 (dd, 1H, $J = 13.1, 5.3$ Hz), 3.71 (s, 3H), 3.84 (s, 3H), 3.96 (d, 1H, $J = 12.2$ Hz), 4.19 (dd, 1H, $J = 12.2, 4.7$ Hz), 4.48 (d, 1H, $J = 8.0$ Hz), 4.82–4.93 (m, 2H), 5.07 (s, 2H), 5.15 (td, 1H, $J = 11.0, 5.4$ Hz), 5.67 (d, 1H, $J = 8.4$ Hz), 7.24–7.33 (m, 5H); ^{13}C NMR (100.53 MHz, CDCl_3) δ 20.7 (2C), 20.9, 34.7, 52.7, 54.2, 62.1, 67.2, 68.3, 68.4, 68.7, 69.0, 97.7, 128.1–128.5 (5C), 136.0, 155.8, 169.8, 170.1, 170.3, 170.7; IR (CHCl_3) ν 3356, 2956, 1740, 1518, 1450, 1132, 1047, 668 cm^{-1} ; HRMS (TOF) m/z [$\text{M} + \text{Na}$] $^+$ calcd for $\text{C}_{24}\text{H}_{31}\text{NNaO}_{12}$ 548.1744, found 548.1753.

Compound 10b. This compound is prepared by the reported procedure¹¹ using **9b** (0.400 g, 0.6 mmol) as the starting material. Yield: (0.202 g, 61%); $[\alpha]_{\text{D}} = +39.8$ ($c = 1.0, \text{CHCl}_3$); ^1H NMR (399.78 MHz, CDCl_3) δ 1.30 (d, 3H, $J = 6.4$ Hz), 1.77 (td, 1H, $J = 12.7, 3.8$ Hz), 2.00 (s, 3H), 2.04 (s, 3H), 2.04 (m, 1H), 2.07 (s, 3H), 3.74 (s, 3H), 3.98–4.07 (m, 2H), 4.27 (dd, 1H, $J = 12.0, 4.9$ Hz), 4.34 (dd, 1H, $J = 6.4, 2.2$ Hz), 4.40 (dd, 1H, $J = 9.7, 2.2$ Hz), 4.88–5.00 (m, 2H), 5.15 (s, 2H), 5.15–5.29 (m, 1H), 5.48 (d, 1H, $J = 9.8$ Hz), 7.31–7.43 (m, 5H); ^{13}C NMR (100.53 MHz, CDCl_3) δ 18.2, 20.6 (2C), 20.9, 35.1, 52.5, 58.5, 62.2, 67.2, 68.3, 68.5, 69.3, 76.2, 98.4, 128.1–128.4 (5C), 136.0, 156.4, 169.8, 170.1, 170.6, 170.9; IR (CHCl_3) ν 3361, 2955, 1742, 1516, 1453, 1128, 1051, 700 cm^{-1} ; HRMS (TOF) m/z [$\text{M} + \text{Na}$] $^+$ calcd for $\text{C}_{25}\text{H}_{33}\text{NNaO}_{12}$ 562.1900, found 562.1909.

Compound 11a. This compound is prepared using the above-mentioned general procedure using **7c** (0.750 g, 1 mmol) as the starting material. Yield: (0.474 g, 73%); $[\alpha]_{\text{D}} = +35.6$ ($c = 1.0, \text{CHCl}_3$); ^1H NMR (399.78 MHz, CDCl_3) δ 2.03 (s, 3H), 2.07 (s, 3H), 2.16 (s, 3H), 3.79 (s, 3H), 3.97 (s, 2H), 4.12 (d, 1H, $J = 10.8$ Hz), 4.20 (t, 3H, $J = 9.9$ Hz), 4.50–4.63 (m, 1H), 4.85 (s, 1H), 5.13 (s, 2H), 5.28 (s, 1H), 5.35 (s, 1H), 5.78 (d, 1H, $J = 7.5$ Hz), 7.29–7.40 (m, 5H); ^{13}C NMR (100.53 MHz, CDCl_3) δ 20.6, 20.7, 20.8, 20.9, 23.8, 52.8, 54.1, 61.9, 65.2, 67.1, 67.6, 68.9, 102.8, 128.0–128.5 (5C), 136.0, 155.8, 169.4, 169.9, 170.0, 170.5; IR (CHCl_3) ν 3361, 2953, 1744, 1517, 1429, 1119, 1053, 669 cm^{-1} ; HRMS (TOF) m/z [$\text{M} + \text{Na}$] $^+$ calcd for $\text{C}_{24}\text{H}_{30}\text{NNaO}_{12}$ 674.0710, found 674.0708.

Compound 11b. This compound is prepared using the above-mentioned general procedure using **7d** (0.750 g, 1 mmol) as the starting material. Yield: (0.478 g, 72%); $[\alpha]_{\text{D}} = +40.4$ ($c = 1.0, \text{CHCl}_3$); ^1H NMR (399.78 MHz, CDCl_3) δ 1.31 (d, 3H, $J = 6.4$ Hz), 2.04 (s, 3H), 2.06 (s, 3H), 2.16 (s, 3H), 3.79 (s, 3H), 4.09 (d, 1H, $J = 5.0$ Hz), 4.11–4.15 (m, 1H), 4.20 (dd, 1H, $J = 11.4, 7.2$ Hz), 4.30–4.35 (m, 1H), 4.37 (dd, 1H, $J = 6.4, 2.3$ Hz), 4.42 (dd, 1H, $J = 9.7, 2.2$ Hz), 4.79–4.84 (m, 1H), 5.14 (s, 2H), 5.30 (s, 1H), 5.35 (s, 1H), 5.46 (d, 1H, $J = 9.7$ Hz), 7.31–7.41 (m, 5H); ^{13}C NMR (100.53 MHz, CDCl_3) δ 18.0, 20.6, 20.7, 20.8, 20.9, 52.7, 58.5, 62.0, 65.0, 65.3, 67.3 (2C), 77.1, 104.0, 128.1–128.5 (5C), 136.0, 156.5, 169.5, 169.9, 170.4, 170.7; IR (CHCl_3) ν 3359, 2951, 1745, 1518, 1452, 1174, 1038, 702 cm^{-1} ; HRMS (TOF) m/z [$\text{M} + \text{Na}$] $^+$ calcd for $\text{C}_{25}\text{H}_{32}\text{IN NaO}_{12}$ 688.0867, found 688.0861.

Compound 12a. This compound is prepared by the reported procedure¹¹ using **11a** (0.400 g, 0.6 mmol) as the starting material. Yield: (0.193 g, 60%); $[\alpha]_{\text{D}} = +62.6$ ($c = 1.0, \text{CHCl}_3$); ^1H NMR (399.78 MHz, CDCl_3) δ 1.76 (dd, 1H, $J = 12.9, 4.9$ Hz), 1.91 (s, 3H), 1.96 (s, 3H), 2.01 (dd, 1H, $J = 12.8, 3.6$ Hz), 2.05 (s, 3H), 3.71 (s, 3H), 3.85 (d, 2H, $J = 3.0$ Hz), 3.99 (m, 3H), 4.44–4.54 (m, 1H), 4.90 (d, 1H, $J = 3.1$ Hz), 5.07 (d, 2H, $J = 1.8$ Hz), 5.12 (dt, 1H, $J = 12.5, 4.2$ Hz), 5.24 (d, 1H, $J = 2.4$ Hz), 5.67 (d, 1H, $J = 8.3$ Hz), 7.23–7.33 (m,

5H); ^{13}C NMR (100.53 MHz, CDCl_3) δ 20.7, 20.7, 20.8, 29.9, 52.7, 54.2, 62.4, 65.8, 66.4, 67.2 (2C), 68.4, 98.2, 128.1–128.5 (5C), 136.0, 155.9, 170.0, 170.2, 170.4, 170.5; IR (CHCl_3) ν 3356, 2956, 1744, 1519, 1449, 1164, 1033, 701 cm^{-1} ; HRMS (TOF) m/z [$\text{M} + \text{Na}$] $^+$ calcd for $\text{C}_{24}\text{H}_{31}\text{N NaO}_{12}$ 548.1744, found 548.1754.

Compound 12b. This compound is prepared by the reported procedure¹¹ using **11b** (0.400 g, 0.6 mmol) as the starting material. Yield: (0.209 g, 63%); $[\alpha]_{\text{D}} = +102.8$ ($c = 1.0, \text{CHCl}_3$); ^1H NMR (399.78 MHz, CDCl_3) δ 1.30 (d, 3H, $J = 6.4$ Hz), 1.70 (dd, 1H, $J = 12.7, 5.0$ Hz), 1.98 (s, 3H), 2.04 (s, 3H), 2.04 (m, 1H), 2.12 (s, 3H), 3.75 (s, 3H), 4.07 (dd, 2H, $J = 6.4, 2.2$ Hz), 4.18 (t, 1H, $J = 6.5$ Hz), 4.35 (dd, 1H, $J = 6.4, 2.1$ Hz), 4.39 (dd, 1H, $J = 9.8, 2.1$ Hz), 4.98 (d, 1H, $J = 3.2$ Hz), 5.15 (s, 2H), 5.15–5.21 (m, 1H), 5.31 (d, 1H, $J = 2.1$ Hz), 5.44 (d, 1H, $J = 9.7$ Hz), 7.32–7.41 (m, 5H); ^{13}C NMR (100.53 MHz, CDCl_3) δ 18.3, 20.6, 20.7, 20.8, 30.2, 52.5, 58.6, 62.5, 65.8, 66.5, 67.1, 67.2, 76.1, 99.1, 128.1–128.5 (5C), 136.0, 156.5, 170.1, 170.2, 170.4, 171.1; IR (CHCl_3) ν 3358, 2955, 1744, 1517, 1452, 1169, 1028, 701 cm^{-1} ; HRMS (TOF) m/z [$\text{M} + \text{Na}$] $^+$ calcd for $\text{C}_{25}\text{H}_{33}\text{NNaO}_{12}$ 562.1900, found 562.1909.

■ ASSOCIATED CONTENT

● Supporting Information

Copies of ^1H , ^{13}C , and DEPT NMR spectra for all compounds, crystallographic data of compound **6e**, and FE-SEM images of micelles. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: s.hotha@iiserpune.ac.in.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

S.H. thanks the DST, New Delhi for the SwarnaJayanthi Fellowship, and M.I. thanks CSIR and N.D.T. thanks IISER Pune for the financial support.

■ REFERENCES

- (1) (a) Escorihuela, J.; Burguete, M. I.; Luis, S. V. *Chem. Soc. Rev.* **2013**, *42*, 5595–5617. (b) Shirakawa, S.; Maruoka, K. *Angew. Chem., Int. Ed.* **2013**, *52*, 4312–4348. (c) Sheldon, R. A. *Chem. Soc. Rev.* **2012**, *41*, 1437–1451. (d) Weissbuch, I.; Lahav, M. *Chem. Rev.* **2011**, *111*, 3236–3267.
- (2) (a) Kunitshima, M.; Kikuchi, K.; Kawai, Y.; Hioki, K. *Angew. Chem., Int. Ed.* **2012**, *51*, 2080–2083. (b) Li, J.; Tang, Y.; Wang, Q.; Xuefeng, L.; Zhang, X.; Zhu, J.; Li, L.; Deng, J. *J. Am. Chem. Soc.* **2012**, *134*, 18522–18525. (c) Van Horn, W. D.; Ogilvie, M. E.; Flynn, P. F. *J. Am. Chem. Soc.* **2009**, *131*, 8030–8039. (d) Correa, N. M.; Zorzan, D. H.; D'Anteo, L.; Lasta, E.; Chiarini, M.; Cerichelli, G. *J. Org. Chem.* **2004**, *69*, 8231–8238.
- (3) (a) Correa, N. M.; Silber, J. J.; Riter, R. E.; Levinger, N. E. *Chem. Rev.* **2012**, *112*, 4569–4602. (b) Klíčov, L.; Šebej, P.; Štacko, P.; Filippov, S.; Bogomolova, A.; Padilla, M.; Klán, P. *Langmuir* **2012**, *28*, 15185–15192. (c) Gaidamauskas, E.; Cleaver, D. P.; Chatterjee, P. B.; Crans, D. C. *Langmuir* **2010**, *26*, 13153–13161.
- (4) (a) Zhdankin, V. V.; Stang, P. J. *Chem. Rev.* **2002**, *102*, 2523–2584. (b) Stang, P. J. *J. Org. Chem.* **2009**, *74*, 2–20.
- (5) (a) Pandit, P.; Gayen, K. S.; Khamarui, S.; Chatterjee, N.; Maiti, D. K. *Chem. Commun.* **2011**, *47*, 6933–6935. (b) Khamarui, S.; Sarkar, D.; Pandit, P.; Maiti, D. K. *Chem. Commun.* **2011**, *47*, 12667–12669. (c) Chatterjee, N.; Pandit, P.; Halder, S.; Patra, A.; Maiti, D. K. *J. Org. Chem.* **2008**, *73*, 7775–7778. (d) Pandit, P.; Chatterjee, N.; Halder, S.; Hota, S. K.; Patra, A.; Maiti, D. K. *J. Org. Chem.* **2009**, *74*, 2581–2584.
- (6) Kirschning, A. *J. Org. Chem.* **1995**, *60*, 1228–1232.
- (7) 2-Deoxy glycosides through hypervalent iodine reagents: (a) Shi, L.; Kim, Y.-J.; Gin, D. Y. *J. Am. Chem. Soc.* **2001**, *123*, 6939–6940.

(b) Kirschning, A.; Plumeier, C.; Rose, L. *Chem. Commun.* **1998**, 33–34. (c) Mironov, Y. V.; Sherman, A. A.; Nifantiev, N. E. *Tetrahedron Lett.* **2004**, *45*, 9107–9110. (d) Kirschning, A.; Hashem, M. A.; Moneneschein, H.; Rose, L.; Schöning, K.-U. *J. Org. Chem.* **1999**, *64*, 6522–6526. (e) Roush, W. R.; Narayan, S.; Bennett, C. E.; Briner, K. *Org. Lett.* **1999**, *1*, 895–897. (f) Kirschning, A.; Jesberger, M.; Schönberger, A. *Org. Lett.* **2001**, *3*, 3623–3626. (g) Hashem, M. A.; Jung, A.; Ries, M.; Kirschning, A. *Synlett* **1998**, 195–197. (h) Rodríguez, M. A.; Boutureira, O.; Arnés, X.; Matheu, M. I.; Díaz, Y.; Castellón, S. *J. Org. Chem.* **2005**, *70*, 10297–10310. 2-Deoxy glycosides without hypervalent iodine reagents: (i) Issa, J. P.; Lloyd, D.; Steliotes, E.; Bennett, C. S. *Org. Lett.* **2013**, *15*, 4170–4173. (j) Kim, K. S.; Park, J.; Lee, Y. J.; Seo, Y. S. *Angew. Chem., Int. Ed.* **2003**, *42*, 459–462. (k) Baryal, K. N.; Zhu, D.; Li, X.; Zhu, J. *Angew. Chem., Int. Ed.* **2013**, *52*, 8012–8016. (l) Tanaka, H.; Yoshizawa, A.; Takahashi, T. *Angew. Chem., Int. Ed.* **2007**, *46*, 2505–2507. (m) Roush, W. R.; Bennett, C. E. *J. Am. Chem. Soc.* **2000**, *122*, 6124–6125. (n) Kirschning, A.; Jesberger, M.; Moneneschein, H. *Tetrahedron Lett.* **1999**, *40*, 8999–9002. (o) Muraki, T.; Yokoyama, M.; Togo, H. *J. Org. Chem.* **2000**, *65*, 4679–4684.

(8) (a) Haukaas, M. H.; O'Doherty, G. A. *Org. Lett.* **2001**, *3*, 3899–3992. (b) Haukaas, M. H.; O'Doherty, G. A. *Org. Lett.* **2002**, *4*, 1771–1774. (c) Yu, X.; O'Doherty, G. A. *Org. Lett.* **2008**, *10*, 4529–4532. (d) Zhou, M.; O'Doherty, G. A. *Org. Lett.* **2008**, *10*, 2283–2286.

(9) Gammon, D. W.; Kinfe, H. K.; De Vos, D. E.; Jacobs, P. A.; Sels, B. F. *Tetrahedron Lett.* **2004**, *45*, 9533–9536.

(10) See Supporting Information for spectral charts, crystallographic data for compound **6e**, and FE-SEM images of micelles.

(11) Quian, Y.; Feng, J.; Parvez, M.; Ling, C.-C. *J. Org. Chem.* **2012**, *77*, 96–107.

(12) Kuposov, A. Y.; Boyarskikh, V. V.; Zhdankin, V. V. *Org. Lett.* **2004**, *6*, 3613–3615.

(13) Crystal data of compound **6e** (CCDC 978459): C₂₀H₂₉INO₁₁, *M* = 586.34, monoclinic, space group *P*2(1), *a* = 9.1343(7), *b* = 6.8955(5), *c* = 20.2243(15) Å, *V* = 1273.56(16) Å³, *Z* = 2, *D*_{calcd} = 1.529 g cm⁻³, *T* = 173(2) K, *μ* = 10.370 mm⁻¹, *F*(000) = 594, *λ* = Cu *Kα* = 1.5418 Å, reflections measured 2979, 2954 unique, observed with *I* > 2σ(*I*), final *R*₁ = 0.0328, *wR*₂ = 0.0830. See Supporting Information for the ORTEP diagram and other details.

(14) (a) Shaikh, A. Y.; Sureshkumar, G.; Pati, D.; Gupta, S. S.; Hotha, S. *Org. Biomol. Chem.* **2011**, *9*, 5951–5959. (b) Pati, D.; Shaikh, A. Y.; Hotha, S.; Gupta, S. S. *Poly. Chem.* **2011**, *2*, 805–811. (c) Pati, D.; Shaikh, A. Y.; Das, S.; Nareddy, P. K.; Swamy, M. J.; Hotha, S.; Gupta, S. S. *Biomacromolecules* **2012**, *13*, 1287–1295.

(15) Weymouth-Wilson, A. C. *Nat. Prod. Rep.* **1997**, *14*, 99–110.

(16) (a) Kessler, V. H.; Kottenhahn, M.; Kling, A.; Kolar, C. *Angew. Chem.* **1987**, *99*, 919–921. (b) Verma, V. P.; Wang, C.-C. *Chem.—Eur. J.* **2013**, *19*, 846–851. (c) Nogueira, J. M.; Nguyen, S. H.; Bennett, C. S. *Org. Lett.* **2011**, *13*, 2814–2817.

(17) For Lewis acid mediated deprotection of silyl ethers under anhydrous conditions: (a) King, S. A.; Pipik, B.; Thompson, A. S.; Decamp, A.; Verhoeven, T. R. *Tetrahedron Lett.* **1995**, *36*, 4563–4566. (b) Shing, T. K. M.; Jiang, Q.; Mak, T. C. W. *J. Org. Chem.* **1998**, *63*, 2056–2057.